A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)
-
Published:2022-08
Issue:4
Volume:7
Page:100529
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Rao S.ORCID, Anandappa G.ORCID, Capdevila J., Dahan L., Evesque L.ORCID, Kim S.ORCID, Saunders M.P., Gilbert D.C.ORCID, Jensen L.H.ORCID, Samalin E., Spindler K.-L.ORCID, Tamberi S.ORCID, Demols A.ORCID, Guren M.G.ORCID, Arnold D., Fakih M.ORCID, Kayyal T., Cornfeld M., Tian C., Catlett M., Smith M., Spano J.-P.ORCID
Subject
Cancer Research,Oncology
Reference56 articles.
1. International trends in anal cancer incidence rates;Islami;Int J Epidemiol,2017 2. Anal cancer incidence in the United States, 1977-2011: distinct patterns by histology and behavior;Shiels;Cancer Epidemiol Biomarkers Prev,2015 3. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021 4. Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP);Moureau-Zabotto;Dig Liver Dis,2017 5. Changing patterns of anal canal carcinoma in the United States;Nelson;J Clin Oncol,2013
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|